Skip to main
PASG

PASSAGE BIO (PASG) Stock Forecast & Price Target

PASSAGE BIO (PASG) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 20%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

Passage Bio is at a crucial stage in their development, with recent safety concerns for their lead programs FTD-GRN and FTD-C9orf72. However, the company has responded appropriately with protocol amendments and is continuing to enroll and dose patients, showing a commitment to their pipeline. The company also has a cash balance of $46.3M and expects it to last into 2027. While the current price target may seem low at $23, the potential upside is significant as the company releases updated biomarker data in the first half of 2026 and receives regulatory feedback on a pivotal trial design later this year.

Bears say

Passage Bio is currently a clinical-stage company, with a single reportable segment focused on gene therapies for neurodegenerative diseases. Their financial outlook is based on a peak revenue analysis with multiple assumptions, and their model assumes dilution in 2026 and 2027. The company is subject to the standard risks of the biotech industry, as well as specific risks such as competition in some indications, manufacturing capacity constraints, and potential delays due to the novelty and complexity of their gene therapy products. Additionally, their lead program PBFT02 faces competition from other companies, and any setbacks in clinical development or unforeseen safety issues could significantly impact their outlook and financial performance.

PASSAGE BIO (PASG) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 20% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PASSAGE BIO (PASG) Forecast

Analysts have given PASSAGE BIO (PASG) a Buy based on their latest research and market trends.

According to 5 analysts, PASSAGE BIO (PASG) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PASSAGE BIO (PASG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.